



## PHARMACEUTICAL 2018









## PHARMACEUTICAL 2018



## **Blueprint Medicines Corp** Rank 73 of 349



The relative strengths and weaknesses of Blueprint Medicines Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Blueprint Medicines Corp compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 264% points. The greatest weakness of Blueprint Medicines Corp is the variable Research and Development, reducing the Economic Capital Ratio by 58% points.

The company's Economic Capital Ratio, given in the ranking table, is 36%, being 314% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	685,505
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	42,890
Liabilities, Non-Current	0
Other Assets	5,869
Other Compr. Net Income	-251
Other Expenses	0
Other Liabilities	0
Other Net Income	3,128
Property and Equipment	24,363
Research and Development	144,687
Revenues	21,426
Selling, General and Administrative Expense	27,986

Output Variable	Value in 1000 USD
Assets	715,737
Liabilities	42,890
Expenses	172,673
Stockholders Equity	672,847
Net Income	-148,119
Comprehensive Net Income	-148,244
Economic Capital Ratio	36%